key: cord-1020422-pmclzhbk
authors: Abadías‐Granado, I.; Navarro‐Bielsa, A.; Morales‐Callaghan, A.M.; Roc, L.; Suso‐Estívalez, C.C.; Povar‐Echeverría, M.; Gilaberte, Y.
title: COVID‐19‐associated cutaneous manifestations: does human herpesvirus 6 play an aetiological role?
date: 2021-03-01
journal: Br J Dermatol
DOI: 10.1111/bjd.19806
sha: c80d08e52945f898172c53b1904bb1a2b468f417
doc_id: 1020422
cord_uid: pmclzhbk

Recently, during the development of COVID-19 pandemic, several publications have warned of possible cutaneous manifestations in association with this novel coronavirus (SARS-CoV-2). In our hospital we have created a multidisciplinary unit with a specific protocol to attend patients with these manifestations. Inclusion criteria consisted of patients who, during the development of the pandemic, were clinically suspected and/or microbiologically confirmed of COVID-19 and had a recent-onset skin rash (within the last 4 weeks). All patients underwent biochemistry, hematimetry and serology for parvovirus B19 and for human herpesvirus 6 (HHV-6), as well as other serologies and a coagulation study according to clinical manifestations. Based on the findings, we also randomly selected 12 hospitalized patients, with similar median age, with COVID-19 but without cutaneous manifestations, and we requested HHV-6 serology. The SARS-CoV-2 antibody assay was Roche´s Elecsys® Anti-SARS-CoV-2 and the HHV-6 antibody assay was ELISA-VIDITEST anti-HHV-6 IgM (Vidia®). The protocol was approved by the Aragon Ethical Committee for Clinical Research.

. In our hospital, we have created a multidisciplinary unit with a specific protocol to attend to patients with these manifestations.

For this study, we included patients who, during the development of the pandemic, were clinically suspected and/or microbiologically confirmed to have COVID-19 and also had a recent-onset skin rash (within the last 4 weeks). All patients underwent biochemistry, haematimetry and serology for parvovirus B19 and for human herpesvirus (HHV)-6, in addition to other serologies and a coagulation study according to clinical manifestations. Based on the findings of these tests, we randomly selected 12 hospitalized patients, of a similar median age, with COVID-19 but without cutaneous manifestations, and we requested HHV-6 serology. The SARS-CoV-2 antibody assay was Roche's Elecsysâ Anti-SARS-CoV-2 (Roche, Basel, Switzerland) and the HHV-6 antibody assay was ELISA-VIDITEST anti-HHV-6 IgM (Vidia, Prague, Czech Republic). The protocol was approved by the Aragon Ethical Committee for Clinical Research.

In total, 53 patients were included between 1 May 2020 and 31 October 2020. Overall, 20 (38%) patients had a positive COVID-19 test and the remaining patients had symptoms suggestive of COVID-19. Unexpectedly, 12 of 53 patients presented IgM serology and/or seroconversion to IgG of HHV-6; the other 41 patients were negative for IgM of HHV-6. Of these 12 patients, only four (33%) tested positive for SARS-CoV-2 [for these 12 patients, the median delay between first symptoms and polymerase chain reaction (PCR) or serology was 3 days and 27Á5 days, respectively]. Characteristics of these patients are summarized in Table 1 .

In the COVID-19 control group, two patients had positive IgM for HHV-6. Statistical analysis performed using Pearson's v 2 -test did not show significant differences between the proportion of patients who were positive for HHV-6 (12 of 53 vs. two of 12) in both groups (P = 0Á64). For the same period of the previous year, 175 HHV-6 IgM serologies were requested, of which only three were positive (all three in children).

Galv an Casas et al. described the following five clinical patterns of cutaneous manifestations associated with SARS-CoV-2: acral areas of erythema with vesicles or pustules (pseudochilblain), other vesicular eruptions, urticarial lesions, maculopapular eruptions and livedo or necrosis. 1 Various hypotheses about the mechanisms inducing the different cutaneous lesions have been proposed. These include immunological responses, hypercoagulability state, drug reactions, a direct cytopathic effect of SARS-CoV-2 or the role of the receptor of SARS-CoV-2, i.e. angiotensin-converting enzyme 2, which was found to be expressed on the skin, mainly on keratinocytes. 2 Alternatively, the role of other viruses, particularly those belonging to the Herpesviridae family, 2 has been suggested, especially in vesicular eruptions, erythema multiforme lesions and pityriasis rosea. 3, 4 In fact, recent reports refer to the increase in frequency of pityriasis rosea after the occurrence of the COVID-19 pandemic. 4, 5 In one case the reactivation of HHV-6 was demonstrated by PCR, 3 and a case of coreactivation of herpes simplex virus 1 and varicella zoster virus in a critically ill patient with COVID-19 was also reported. 6 In this regard, we want to highlight the finding of positive IgM serology for HHV-6 in our series of patients. Cutaneous diseases that have been associated with HHV-6 infection include roseola infantum, pityriasis rosea, Gianotti-Crosti syndrome, drug reaction with eosinophilia and systemic symptoms or thrombocytopenic purpura, among others. 7 Nevertheless, an aetiological association between HHV-6 infection and a cutaneous disease is complicated by the ubiquity and nearly universal prevalence of the virus. In addition, several samples over time are needed to demonstrate seroconversion, which is considered an indispensable requirement to prove the active pathological role of the virus. 7 However, serology as a diagnostic procedure has disadvantages and limitations, such as a lack of interpretation for the diagnosis of reactivations or cross-reactivity with other betaherpesviruses. 8 As our patients do not share clinical characteristics, and the difference in the proportion of both groups is not statistically significant, it is very difficult to be sure that HHV-6 has played an aetiological role in the development of cutaneous manifestations. However, it is even more difficult to attribute cutaneous manifestations to SARS-CoV-2 given the negative results of several microbiological tests, even repeatedly, in some of these patients. Thus, we want to emphasize the finding of a positive serology for HHV-6 in different clinical patterns described in association with COVID-19. We suggest that SARS-CoV-2 could cause the reactivation of other viruses, such as HHV-6, which could be responsible for some cutaneous manifestations initially related to COVID-19. The main limitation of our study is that only 38% of the patients were positive for SARS-CoV-2 (33% in the HHV-6 group). Therefore, more studies are necessary to demonstrate the association between SARS-CoV-2 and HHV-6, and its possible aetiological role in COVID-19-associated cutaneous manifestations.

I. Abad ıas-Granado iD , 1 A. Navarro-Bielsa, 1 A.M. Morales-Callaghan, 1 L. Roc, 2 C.C. Suso-Est Ivalez, 3 M. Povar-Echeverr Ia 3 and Y. Gilaberte 1

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms

Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19

The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease

Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic

Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19

Human herpesviruses 6, 7, and 8 from a dermatologic perspective

Laboratory and clinical aspects of human herpesvirus 6 infections

Conflicts of interest: The authors declare they have no conflicts of interest